Additionally, studies have suggested that circulating plasma-derived exosomes with ACE-2 from disease-free individual and convalescent COVID-19 patients have the ability to inhibit the attaching viral S protein to surface binding sites [60,61,62,63]. This evidence concerns the gene ACE2 and COVID-19.